Publications
Detailed Information
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Schuler, Martin | - |
dc.contributor.author | Tan, Eng-Huat | - |
dc.contributor.author | O'Byrne, Kenneth | - |
dc.contributor.author | Zhang, Li | - |
dc.contributor.author | Boyer, Michael | - |
dc.contributor.author | Mok, Tony | - |
dc.contributor.author | Hirsh, Vera | - |
dc.contributor.author | Yang, James Chih-Hsin | - |
dc.contributor.author | Lee, Ki Hyeong | - |
dc.contributor.author | Lu, Shun | - |
dc.contributor.author | Shi, Yuankai | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Laskin, Janessa | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Arvis, Catherine Dubos | - |
dc.contributor.author | Kolbeck, Karl | - |
dc.contributor.author | Massey, Dan | - |
dc.contributor.author | Maerten, Angela | - |
dc.contributor.author | Paz-Ares, Luis | - |
dc.contributor.author | Park, Keunchil | - |
dc.date.accessioned | 2020-04-27T10:55:55Z | - |
dc.date.available | 2020-04-27T10:55:55Z | - |
dc.date.created | 2020-04-09 | - |
dc.date.issued | 2019-06 | - |
dc.identifier.citation | Journal of Cancer Research and Clinical Oncology, Vol.145 No.6, pp.1569-1579 | - |
dc.identifier.issn | 0171-5216 | - |
dc.identifier.other | 95456 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165199 | - |
dc.description.abstract | PurposeIn the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with treatment-naive epidermal growth factor receptor mutation-positive non-small cell lung cancer. We report post hoc analyses of tolerability-guided dose adjustment for afatinib and summarize the clinical characteristics of patients who continued afatinib/gefitinib beyond initial radiological progression in LUX-Lung 7.MethodsPatients received afatinib 40mg/day or gefitinib 250mg/day until investigator-assessed progression or beyond if beneficial. In case of selected treatment-related adverse events (TRAEs), the afatinib dose could be reduced by 10-mg decrements to minimum 20mg (only dose interruptions were permitted with gefitinib).ResultsAll randomized patients were treated (afatinib, n=160; gefitinib, n=159). Sixty-three patients had afatinib dose reduction (<40mg/day; 47 within first 6 months). Dose reduction decreased TRAE incidence/severity (before vs after; all grade/grade 3: 100.0%/63.5% vs 90.5%/23.8%). There was no evidence of significant difference in PFS for patients who received<40mg/day vs40mg/day for the first 6 months [median: 12.8 vs 11.0 months; hazard ratio 1.34 (95% confidence interval 0.90-2.00)]. Twenty-four and 26 patients continued afatinib and gefitinib, respectively, beyond progression in target lesions; median time from nadir of target lesion diameters to initial progression was 6.7 months and 5.6 months. Of these patients, similar to 70% had objective response or non-complete response/non-progressive disease in non-target lesions at initial progression.ConclusionsProtocol-defined dose adjustment of afatinib may allow patients to remain on treatment longer, maximizing clinical benefit even in the presence of radiological progression. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1007/s00432-019-02862-x | - |
dc.citation.journaltitle | Journal of Cancer Research and Clinical Oncology | - |
dc.identifier.wosid | 000468537100016 | - |
dc.identifier.scopusid | 2-s2.0-85061727826 | - |
dc.citation.endpage | 1579 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 1569 | - |
dc.citation.volume | 145 | - |
dc.identifier.sci | 000468537100016 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | ACQUIRED-RESISTANCE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | DISCONTINUATION | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | ERLOTINIB | - |
dc.subject.keywordAuthor | Afatinib | - |
dc.subject.keywordAuthor | EGFR | - |
dc.subject.keywordAuthor | NSCLC | - |
dc.subject.keywordAuthor | Dose adjustment | - |
dc.subject.keywordAuthor | Time-to-treatment failure | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.